Earnings call transcript: Fosun International posts H1 2026 profit surge
Hamlet BioPharma announced its plans to advance to Phase III clinical trials for its bladder cancer program in Q4 2026. The Swedish biotech experienced clinical progress, a capital raise, and ongoing partnership discussions during the quarter. Hamlet's lead cancer candidate, Alpha1H, demonstrated an 82% complete or partial response rate in a Phase II study.
The company's cash position is sufficient to begin Phase III trials at its current burn rate, which is about 3.5 million SEK per quarter. With a market capitalization of $118.6 million, Hamlet BioPharma is currently trading above its 52-week high of $0.94 but below its 52-week low of $0.42. The company has raised $25.7 million SEK through warrant exercises in July and August, giving it a cash runway to fund operations into 2027.
Hamlet is exploring a broader pipeline that includes infection therapies, tuberculosis research, and a chronic pain program. The company is also considering combination studies with existing treatments like mitomycin or BCG. Hamlet BioPharma's chairman, Catharina Svanborg, highlighted the company's cost advantage compared to large pharmaceutical companies, stating that Hamlet has a lower cost image.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
